Tacrolimus ointment in nickel sulphate-induced steroid-resistant allergic contact dermatitis

Allergy and Asthma Proceedings

Volumn 27, Issue 6, 2006, Pages 527-531

  Pacor, Maria L ^a,b   Di Lorenzo, Gabriele ^a,c   Martinelli, Nicola ^a,b   Mansueto, Pasquale ^a,c   Friso, Simonetta ^a,b   Pellitteri, Maria Esposito ^a,c   Di Fede, Gaetana ^a,c   Rini, GiovamBattista ^a,c   Corrocher, Roberto ^a,b  

^a Università degli Studi di Verona ^*

^b UNIVERSITY OF PALERMO   (Italy)

^c Dipartimento di Medicina Clinica e delle Patologie Emergenti   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; IRRITANT AGENT; NICKEL; NICKEL SULFATE; TACROLIMUS;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG RESISTANCE; FEMALE; HUMAN; MALE; MIDDLE AGED; OINTMENT; RANDOMIZED CONTROLLED TRIAL; SKIN ALLERGY;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; DERMATITIS, ALLERGIC CONTACT; DOUBLE-BLIND METHOD; DRUG RESISTANCE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IRRITANTS; MALE; MIDDLE AGED; NICKEL; OINTMENTS; TACROLIMUS;

EID: 33845488144     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: 10.2500/aap.2006.27.2915     Document Type: Article

References (28)

1. Hachem JP, De Paepe K, Vanpee E, et al. Efficacy of topical corticosteroids in nickel-induced contact allergy. Clin Exp Dermatol 27:47-50, 2002.
2. Tocci MJ, Matkovich DA, Collier KA, et al. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol 143:718-726, 1989.
3. Panhans-Groß A, Novak N, Kraft S, et al. Human epidermal Langerhans cells are targets for the immunosuppressive macrolide tacrolimus (FK506). J Allergy Clin Immunol 107:345-352, 2001.
4. Wollenberg A, Sharma S, von Bubnoff D, et al. Topical tacrolimus FK506) leads to profound phenotypic and functional alterations of epidermal antigen presenting dendritic cells in atopic dermatitis. J Allergy Clin Immunol 107:519-525, 2001.
5. Cheer SM, and Plosker GL. Tacrolimus ointment. A review of its therapeutic potential as a topical therapy in atopic dermatitis. Am J Clin Dermatol 2:389-406, 2001.
6. Ruzicka T, Bieber T, Schopf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med 337:816-821, 1997.
7. Kang S, Lucky AW, Pariser D, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 44(suppl):S58-S64, 2001.
8. Kapp A, Allen BR, and Reitamo S. Atopic dermatitis management with tacrolimus ointment (Protopic). J Dermatol Treat 14(suppl 1)5-16, 2003.
9. Pacor ML, Di Lorenzo G, Martinelli N, et al. Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: A randomized study. Clin Exp Allergy 34:639-645, 2004.
10. Reitamo S, Ortonne JP, Sand C, et al. European Tacrolimus Ointment Study Group. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol 152:1282-1289, 2005.
11. Yamamoto T, and Nishioka K. Topical tacrolimus: An effective therapy for facial psoriasis. Eur J Dermatol 13:471-473, 2003.
12. Hodgson TA, Sahni N, Kaliakatsou F, et al. Long-term efficacy and safety of topical tacrolimus in the management of ulcerative/erosive oral lichen planus. Eur J Dermatol 13:466-470, 2003.
13. Lener EV, Brieva J, Schachter M, et al. Successful treatment of erosive lichen planus with topical tacrolimus. Arch Dermatol 137:419-422, 2001.
14. Nazzaro G, and Cestari R. Topical tacrolimus ointment in ulcerative lichen planus: An alternative therapeutic approach. Eur J Dermatol 12:321, 2002.
15. Morrison L, Kratochvil FJ III, and Gorman A. An open trial of topical tacrolimus for erosive oral lichen planus. J Am Acad Dermatol 47:617-620, 2002.
16. Richter-Hintz D, Schuppe HC, Homey B, et al. Topical tacrolimus (FK 506) is effective in the treatment of pyoderma gangrenosum. J Am Acad Dermatol 42:304-305, 2000.
17. Reich K, Vente C, and Neumann C. Topical tacrolimus for pyoderma gangrenosum. Br J Dermatol 139:755-757, 1998.
18. Bamford JT, Elliott BA, and Haller IV. Tacrolimus effect on rosacea. J Am Acad Dermatol 50:107-108, 2004.
19. Goldman D. Tacrolimus ointment for the treatment of steroid-induced rosacea: A preliminary report. J Am Acad Dermatol 44:995-998, 2001.
20. Nakada T, Iijima M, and Maibach HI. Eyeglass frame allergic contact dermatitis: Does tacrolimus prevent recurrences? Contact Derm 53:219-221, 2005.
21. Anderson BE, Marks JG Jr, and Mauger DT. Efficacy of tacrolimus ointment in the prevention and treatment of contact dermatitis. Dermatitis 15:158-159, 2004.
22. Queille-Roussel C, Graeber M, Thurston M, et al. SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge. Contact Derm 42:349-350, 2000.
23. Saripalli YV, Gadzia JE, and Belsito DV. Tacrolimus ointment 0.1% in the treatment of nickel-induced allergic contact dermatitis. J Am Acad Dermatol 49:477-482, 2003.
24. Alomar A, Puig L, Gallardo CM, et al. Topical tacrolimus 0.1% ointment (protopic) reverses nickel contact dermatitis elicited by allergen challenge to a similar degree to mometasone furoate 0.1% with greater suppression of late erythema. Contact Derm 49:185-188, 2003.
25. De Rie MA, Meinardi MM, and Bos JD. Lack of efficacy of topical cyclosporin A in atopic dermatitis and allergic contact dermatitis. Acta Derm Venereol 71:452-454, 1991.
26. Bieber T, Cork M, Ellis C, et al. Consensus statement on the safety profile of topical calcineurin inhibitors. Dermatology 211: 77-78, 2005.
27. Del Rosso J, and Friedlander SF. Corticosteroids: Options in the era of steroid-sparing therapy. J Am Acad Dermatol 53(suppl 1):S50-S58, 2005.
28. Fonacier L, Spergel J, Charlesworth EN, et al. American College of Allergy, Asthma and Immunology; American Academy of Allergy, Asthma and Immunology. Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 115:1249-1253, 2005.